Related Experiment Video
Updated: Apr 16, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
Published on: October 25, 2013
Antimicrobial Activity of Plectasin NZ2114 in Combination with Cell Wall Targeting Antibiotics Against VanA-Type
Elena B M Breidenstein1, Patrice Courvalin1, Djalal Meziane-Cherif1
1Department of Microbiology, Unité des Agents Antibactériens, Institut Pasteur , Paris, France .
Abstract:
Antimicrobial peptide plectasin targeting bacterial cell wall precursor Lipid II has been reported to be active against benzylpenicillin-resistant Streptococcus pneumoniae but less potent against vancomycin-resistant enterococci than their susceptible counterparts. The aim of this work was to test plectasin NZ2114 in combination with cell wall targeting antibiotics on vancomycin-resistant Enterococcus faecalis. The activity of antibiotic combinations was evaluated against VanA-type vancomycin-resistant E. faecalis strain BM4110/pIP816-1 by disk agar-induction, double-disk assay, determination of fractional inhibitory concentration (FIC) index, and time-kill curve. The results indicated that plectasin NZ2114 was synergistic in combination with teicoplanin, moenomycin, and dalbavancin but not with vancomycin, telavancin, penicillin G, bacitracin, ramoplanin, daptomycin, and fosfomycin. To gain an insight into the synergism, we tested other cell wall antibiotic combinations. Interestingly, synergy was observed between teicoplanin or moenomycin and the majority of the antibiotics tested; however, vancomycin was only synergistic with penicillin G. Other cell wall active antibiotics such as ramoplanin, bacitracin, and fosfomycin did not synergize. It appeared that most of the synergies observed involved inhibition of the transglycosylation step in peptidoglycan synthesis. These results suggest that teicoplanin, dalbavancin, vancomycin, and telavancin, although they all bind to the C-terminal D-Ala-D-Ala of Lipid II, might act on different stages of cell wall synthesis.
Insights
Antimicrobial peptide plectasin NZ2114 shows synergy with teicoplanin, moenomycin, and dalbavancin against vancomycin-resistant Enterococcus faecalis. These combinations may target different stages of bacterial cell wall synthesis, offering new therapeutic strategies.
Area of Science:
- Microbiology
- Pharmacology
- Biochemistry
Background:
- Antimicrobial peptide plectasin exhibits activity against resistant bacteria.
- Vancomycin-resistant Enterococcus faecalis (VRE) poses a significant clinical challenge.
- Plectasin's efficacy against VRE is less understood compared to other resistant strains.
Purpose of the Study:
- To evaluate the synergistic activity of plectasin NZ2114 in combination with cell wall-targeting antibiotics against vancomycin-resistant Enterococcus faecalis (VRE).
- To investigate the mechanisms underlying observed synergistic interactions.
- To explore potential novel therapeutic strategies for VRE infections.
Main Methods:
- Disk agar-induction, double-disk assay, fractional inhibitory concentration (FIC) index determination, and time-kill curve analyses were employed.
- Combinations of plectasin NZ2114 with various cell wall synthesis inhibitors were tested against VanA-type VRE.
- Further synergistic interactions between other cell wall antibiotics were assessed.
Main Results:
- Plectasin NZ2114 demonstrated synergistic effects when combined with teicoplanin, moenomycin, and dalbavancin against VRE.
- Synergy was not observed with vancomycin, telavancin, penicillin G, bacitracin, ramoplanin, daptomycin, or fosfomycin.
- Teicoplanin and moenomycin showed broad synergy with other antibiotics, suggesting involvement in peptidoglycan transglycosylation inhibition.
Conclusions:
- Plectasin NZ2114 can potentiate the activity of specific cell wall-targeting antibiotics against VRE.
- The observed synergies, particularly with teicoplanin and moenomycin, likely involve the inhibition of peptidoglycan transglycosylation.
- These findings suggest that combinations targeting different stages of cell wall synthesis may offer effective therapeutic options against VRE.
More Related Videos
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Clinical Significance of Antibiotic Resistance
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Antimicrobial Effectiveness
Gene Regulation in Microbial Communities: Quorum Sensing
Development of Antibiotic Resistance

